多囊卵巢综合征患者性激素、血脂、体重指数与抗缪勒氏管激素异常的相关性分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the correlation of sex hormone, blood lipid and body mass index (BMI) with antimullerian hormone (AMH) abnormality in patients with polycystic ovarian syndrome (PCOS). Methods A total of 50 patients with PCOS who admitted to the hospital from January 2018 to December 2019 as the research objects were included in observation group, and 50 healthy controls during the same period in our hospital were included in control group. The AMH, sex hormones (luteinizing hormone [LH], follicle stimulating hormone [FSH], prolactin [PRL], estradiol [E2], testosterone [TESTO], progesterone [PROG]), blood lipid (total cholesterol [CHOL], triglyceride [TG]) contents and BMI of all PCOS patients and healthy controls were measured in serum samples from both groups, and the correlation of sex hormone, blood lipid, BMI and AMH in PCOS patients were analyzed. Results The BMI, LH, E2, TESTO,CHOL, TG and AMH in observation group were higher than those in control group, and the PRL, FSH, PROG in observation group were lower than those in control group, and the differences were statistically significant (P＜0.05). Pearson analysis showed that the levels of BMI, LH, E2, TESTO, CHOL and TG in PCOS patients were positively correlated with AMH (r＞0, P＜0.05). The PRL, FSH and PROG were negatively correlated with AMH (r＜0, P＜0.05). Conclusion The serum AMH has certain correlation with sex hormone (LH, FSH, PRL, E2, TESTO, PROG), blood lipid (CHOL, TG) and BMI in patients with PCOS. Therefore, early screening, treatment and prevention for PCOS patients have certain clinical significance.

Key words： Polycystic ovarian syndrome Sex hormone;Blood lipid Body mass index Anti-mullerian hormone;Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jing

Cite this article:

WANG Jing. Correlation analysis of sex hormone, blood lipid and body mass index with anti-mullerian hormone abnormality in patients with polycystic ovarian syndrome[J]. 中国当代医药, 2020, 27(25): 190-193.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I25/190

[1]	张翌蕾，潘文，汪永娟，等.多囊卵巢综合征病因病机中西医研究进展[J].中国中医基础医学杂志，2016，22（7）：1004-1006.
[2]	林评樱，胡嘉华，吴媛，等.抗苗勒管激素（AMH）在生殖内分泌方面的临床应用价值研究[J].中医临床研究，2019，11（6）：58-59.
[3]	王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社，2010：943.
[4]	谢幸，孔北华，段涛，等.妇产科学[M].9 版.北京：人民卫生出版社，2018：348-349.
[5]	Thaweekul P，Thaweekul Y，Mairiang K.A huge ovarian mucinous cystadenoma associated with contralateral teratoma and polycystic ovary syndrome in an obese adolescent girl[J].Asia Pac J Clin Nutr，2016，25（4）：920-923.
[6]	谭容容，吴洁.多囊卵巢综合征诊断的潜在新指标[J].中华生殖与避孕杂志，2017，37（12）：995-1002.
[7]	刘文英，季新梅，游华蓉.促甲状腺激素水平与多囊卵巢综合征患者性激素、血脂及胰岛素抵抗的关系[J].中国综合临床，2018，34（5）：455-459.
[8]	杜静，李嘉丽，晏耀明，等.多囊卵巢综合征患者血清AMH，LH 和FSH 水平检测及临床应用研究[J].现代检验医学杂志，2019，34（5）：68-71.
[9]	彭娟娟.不同体重类型多囊卵巢综合征患者证素特征及其与性激素水平的相关性研究[D].福州：福建中医药大学，2017.
[10]	崔雄鹰，胡杰，阴振晨，等.多囊卵巢综合征患者血清相关性腺激素结果分析[J].标记免疫分析与临床，2019，26（8）：1282-1285.
[11]	陈淑琴，米东，段敏，等.高雄激素血症多囊卵巢综合征患者性激素和胰岛素水平分析[J].中国计划生育学杂志，2018，26（12）：101-103.
[12]	张秋敏.血清抗缪勒氏管激素分析在多囊卵巢综合征中的临床应用研究[J].中国医药科学，2019，9（9）：237-239.
[13]	李洁.抗缪勒氏管激素诊断多囊卵巢综合征的价值分析[J].医学理论与实践，2018，31（20）：3022-3024.
[14]	温国辉，孙志豪，李庆.血清抗缪勒氏管激素（AMH）诊断多囊卵巢综合征的价值观察[J].中国医药科学，2018，8（20）：114-116.
[15]	胡平.抗缪勒氏管激素在多囊卵巢综合征诊断中的临床价值[J].成都医学院学报，2018，13（4）：490-492.